The Impact of Passive Heat Treatment on Glycaemic Response During an Oral Glucose Tolerance Test in Diabetic Patients

Diabetes Mellitus, Type 2 Clinical Trial

— Sauna-OGTT  

Official title:

The Impact of Passive Heat Treatment on Glycaemic Response During an Oral Glucose Tolerance Test in Diabetic Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05610046
• Other study ID #: METC 22-057
• Status: Active, not recruiting
• Phase: N/A
• Start date: January 26, 2023
• Est. completion date: December 31, 2023

Study information

• Verified date: May 2023
• Source: Maastricht University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Type 2 diabetes mellitus (T2DM) is a metabolic disease with a rapidly increasing incidence world-wide. The disease is characterizedby a decreased glucose tolerance as a result of insulin resistance, resulting in poor blood glycaemic control. Blood glucose loweringmedications are widely available, but their effect stagnates as T2DM progresses. New treatment regimens are required to combatthe disease. Although therapies such as physical exercise have been shown to induce beneficial effects on glycaemic control inT2DM patients, not all patients are able to perform exercise. Passive heating treatment (PHT) might be an alternative strategy toreduce insulin resistance, as it has been postulated to have comparable effects on the cardiovascular system as exercise. PHT hasbeen linked to numerous health benefits, including improved cardiovascular- and pulmonary function, pain alleviation and metabolichealth. In addition, long term use of PHT shows promising effects on glycaemic control in T2DM patients. However, the acute effectsof PHT on glucoregulation are yet to be determined. Therefore, in this study we will assess the acute impact of passive heat treatment on the post-prandial glycaemic response during an OGTT in T2DM patients

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 12
• Est. completion date: December 31, 2023
• Est. primary completion date: April 14, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Aged =50 years old

• Body mass index 18.5 - 35 kg/m2

• DM type 2

• Using oral blood glucose lowering medication

• Able to give informed consent

Exclusion Criteria:

• Insulin dependence

• Changes in diabetes medication in the past 3 months

• Allergy for one of the food items used

• >5% weight change in the previous 6 months

• Participating in a structured (progressive) exercise program, or in the past 3 months.

• Frequent (once per week or more) user of infrared (or traditional) sauna in the past 3 months

• Inability to tolerate sauna/high temperatures

• Smoking

• Diagnosed with cardiovascular disease (e.g. unstable angina pectoris or recent myocardial infarction), kidney failure (eGFR < 60 ml/min/1.73m2), rheumatoid arthritis

• Diagnosed musculoskeletal, GI tract, metabolic (except diabetes) or pulmonary (e.g. COPD) disorders that are expected to influence study outcomes

• Having a pacemaker, defibrillator, or any other type of metal implant

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2

Intervention

Device:
• Infrared sauna heating
Participants will sit in an infrared sauna at 60° Celsius (humidity not controlled in an infrared sauna) for a total of 40 minutes.
• Sham sauna
Participants will sit in an inactive infrared sauna at room temperature (21° Celsius) for a total of 40 minutes.

Locations

Country	Name	City	State
Netherlands	Maastricht University Medical Centre +	Maastricht

Sponsors (1)

Lead Sponsor	Collaborator
Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Glycaemic response (Matsuda index)	OGTT	120 minutes
Secondary	HOMA-IR	fasting glucose and insulin values	Baseline
Secondary	Plasma volume/hematocrit		Throughout test day (3h)
Secondary	Gutt insulin sensitivity index	from OGTT values	120 minutes